Shows "statistically significant dose response trends and pairwise comparisons with placebo" in a 12-week placebo-controlled multicenter study of the Alzheimer's drug candidate in 468 patients, company reports at Third International Conference on Alzheimer's Disease and Related Disorders in Padua, Italy July 17. Using doses of Cognex (tacrine) of up to 80 mg/day, "over 50% of treated patients showed improvement on the ADAS Cognitive test." The results also show that "63% of patients were rated as improved by the study clinician and 56% of patients were rated as improved by the caregiver (versus 33% and 28% of patients on placebo, respectively)," Warner-Lambert said. The Cognex expanded access program and a high-dose (120 mg-160 mg) parallel group study are ongoing ("The Pink Sheet" June 22, In Brief).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth